← boardnext 2026-08next 2029-06
RIGL
Rigel Pharmaceuticalsdistress 0/10 · well-funded / low risk$36.64-3%today-28% from 52w high
Lead: Astrocytoma
Revenue
$59M
Liquidity
$147M
Runway
—
Shares 1y
+3%
Price & events
-3.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.1%
1D
-12.1%
1W
+2.9%
1M
+19.3%
3M
-0.9%
6M
+73.9%
1Y
+248.0%
2Y
-11.1%
5Y
+5.6%
All
Overview
- Market Cap
- $677.92M
- Enterprise Value
- $698.51M
- Volume
- 38.61K
- 52 Week Range
- $18.80 – $50.96
- Total Shares
- 18.50M
- Float Shares
- 15.94M
- Short %
- 18.05%
- % Held by Insiders
- 3.39%
- % Held by Institutions
- 94.11%
- RVOL
- 0.10x
- Beta
- 1.13
Pipeline stages · 2 programs
R906289 Monosodium (R289 Na)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Olutasidenib, TMZ
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-09-15 | Phase 1/2 | R906289 Monosodium (R289 Na) | Low Risk Myelodysplastic Syndromes | 86 | recruiting |
| 2029-06 Estimated 50% readout ~2029-07-16 | Phase 2 | Olutasidenib, TMZ | High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma | — | recruiting |
Catalyst news & presentations · 6
- second half of 2026Guided 55%enrollment completesecondaryPhase 1R289 · Complete enrollment and select recommended Phase 2 doseSEC 8-K
- by the end of 2026Guided 40%readoutPhase 1R289 · Share preliminary data from dose expansion phaseSEC 8-K
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025trial initiationsecondaryPhase 2olutasidenib · Plan to initiate Phase 2 study in recurrent glioma.SEC 8-K
- December 7, 2025conferencedata presentationsecondaryPhase 1R289 · Updated data from Phase 1b study presented at ASHSEC 8-K
- 2025-03-27partnershipfostamatinib · Settlement agreement with Annora granting license to sell generic TAVALISSE in Q2 2032.SEC 8-K
Approved drugs (3)
- REZLIDHIAOLUTASIDENIB2022 · Prescription
- GAVRETOPRALSETINIB2020 · Prescription
- TAVALISSEFOSTAMATINIB DISODIUM2018 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $54 (+48% upside) · 5 analysts
- 2026-06-02HC Wainwright & Co.Buy
- 2026-05-27HC Wainwright & Co.Buy
- 2026-05-22HC Wainwright & Co.Buy
- 2026-05-13CitigroupBuy
- 2026-05-07CitigroupBuy
- 2025-11-05JefferiesHold → Buy
Competitors — Astrocytoma
Recent news
- 2026-07-11Form 4 Rigel Pharmaceuticals Inc For: 10 July By Investing.com - Investing.com Canada
- 2026-07-10Rigel Pharmaceuticals (RIGL) CMO receives 24,400-share RSU equity award with 4-year vesting - Stock Titan
- 2026-07-07Rigel Pharmaceuticals (RIGL) Q1 2026 earnings summary - Quartr
- 2026-07-07Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
- 2026-07-07Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
- 2026-07-07Rigel awards new hires 13,375 RSUs under its inducement plan - Stock Titan
- 2026-07-01Rigel Pharmaceuticals Appoints Dr. Alison L. Hannah as CMO (RIGL) - GuruFocus
- 2026-07-01Rigel Pharmaceuticals Appoints Alison L. Hannah as Chief Medical Officer - citybiz
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.